PMID- 9892111
OWN - NLM
STAT- MEDLINE
DCOM- 19990611
LR  - 20191024
IS  - 1045-2257 (Print)
IS  - 1045-2257 (Linking)
VI  - 24
IP  - 1
DP  - 1999 Jan
TI  - der(16)t(1;16)/der(1;16) in breast cancer detected by fluorescence in situ 
      hybridization is an indicator of better patient prognosis.
PG  - 72-7
AB  - By two-color fluorescence in situ hybridization (FISH), der(16)t(1;16) or 
      der(1;16) was frequently detected in low-grade papillary carcinoma but not in 
      benign intraductal papilloma of the breast. In order to clarify the incidence and 
      clinicopathological significance of der(16)t(1;16)/der(1;16) in common breast 
      cancers, der(16)t(1;16)/der(1;16) was examined by two-color FISH in breast 
      cancers resected from 51 patients by using DNA probes for 16cen, 16q11.2, and 
      1q12 labeled with biotin or digoxigenin. der(16)t(1;16)/der(1;16) was clonally 
      detected in 16 cancers (31%), being more frequent in ductal carcinomas of lower 
      grade and invasive lobular carcinoma than in high-grade invasive ductal carcinoma 
      (P<0.001). der(16)t(1;16)/der(1;16) was also correlated with a higher amount of 
      hormone receptors in the tumor (P<0.05). Disease-free and overall survival rates 
      of the patient group with der(16)t(1;16)/der(1;16)-positive cancer were higher 
      (88% and 94%) than those of the group with der(16)t(1;16)/der(1; 16)-negative 
      cancer (39% and 68%) (P<0.05). Among the 16 patients with lymph node metastasis 
      who received one of two similar forms of postsurgical adjuvant chemo-endocrine 
      therapy, the prognosis of those with der(16)t(1;16)/der(1;16)-positive cancer was 
      better than that of those with der(16)t(1;16)/der(1;16)-negative cancer (P<0.05). 
      der(16)t(1;16)/der(1;16) detected by FISH is considered helpful in identifying 
      patients with a better prognosis and for stratification of patients in randomized 
      clinical trials of adjuvant chemo-endocrine therapies.
FAU - Tsuda, H
AU  - Tsuda H
AD  - Pathology Division, National Cancer Center Research Institute, Tokyo, Japan. 
      hstsuda@gan2.ncc.go.jp
FAU - Takarabe, T
AU  - Takarabe T
FAU - Fukutomi, T
AU  - Fukutomi T
FAU - Hirohashi, S
AU  - Hirohashi S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Genes Chromosomes Cancer
JT  - Genes, chromosomes & cancer
JID - 9007329
RN  - 0 (DNA Probes)
RN  - 0 (DNA, Neoplasm)
RN  - 0 (Genetic Markers)
SB  - IM
MH  - Breast Neoplasms/*diagnosis/*genetics
MH  - Chromosomes, Human, Pair 1/*genetics
MH  - Chromosomes, Human, Pair 16/*genetics
MH  - DNA Probes
MH  - DNA, Neoplasm
MH  - Female
MH  - Genetic Markers
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/methods
MH  - Prognosis
MH  - *Translocation, Genetic
EDAT- 1999/01/19 03:02
MHDA- 2000/06/20 09:00
CRDT- 1999/01/19 03:02
PHST- 1999/01/19 03:02 [pubmed]
PHST- 2000/06/20 09:00 [medline]
PHST- 1999/01/19 03:02 [entrez]
AID - 10.1002/(SICI)1098-2264(199901)24:1<72::AID-GCC10>3.0.CO;2-M [pii]
AID - 10.1002/(sici)1098-2264(199901)24:1<72::aid-gcc10>3.0.co;2-m [doi]
PST - ppublish
SO  - Genes Chromosomes Cancer. 1999 Jan;24(1):72-7. doi: 
      10.1002/(sici)1098-2264(199901)24:1<72::aid-gcc10>3.0.co;2-m.